Company: SMNR
Filing Date: 2025-06-11
Form Type: S-4/A
Source: 0001193125-25-139124
Chunk: 453

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-06-11
Form: S-4/A
Chunk 453
---
, pursuant to which, among other things, immediately following the consummation of the acquisitions by Longevity of each of Cerevast Medical, Inc., Aegeria Soft Tissue LLC, and Novokera LLC, (i) the Denali-Longevity Merger would occur, with Denali as the surviving entity of the Denali-Longevity Merger, and (ii) the Longevity Merger would occur, with Longevity as the surviving company of the Longevity Merger. Following the Denali-Longevity Merger and Longevity Merger, each of Longevity and Denali would be a subsidiary of Holdco, and Holdco would become a publicly traded company.

On June 26, 2024, pursuant to Section 11.1(a) of the Merger Agreement, the parties entered into the Termination Agreement pursuant to which the Longevity Merger Agreement was terminated effective as of the date of the Termination Agreement.

As a result of the Termination Agreement, the Longevity Merger Agreement is of no further force and effect (other than certain customary limited provisions that survive the termination pursuant to the terms of the Longevity Merger Agreement) and ancillary agreements entered into in connection with the Longevity Merger Agreement also automatically terminated in accordance with their respective terms. As a result of the termination of the Longevity Merger Agreement, Holdco withdrew its registration statement on Form S-4, as amended, initially filed with the SEC on March 29, 2023.

On July 10, 2024, Denali held the Second Extension Meeting to consider and vote upon the Second Extension Amendment Proposal to extend the date by which Denali must: (i) consummate a merger, share exchange, asset

<div align='center'>276</div>

acquisition, share purchase, reorganization or similar business combination involving Denali and one or more businesses or entities; (ii) cease its operations, except for the purpose of winding up, if it fails to complete such initial business combination; and (iii) redeem 100% of the Denali Ordinary Shares, included as part of the Public Units sold in the IPO from July 11, 2024 to April 11, 2025, by electing to extend the date to consummate an initial business combination on a monthly basis for up to nine (9) times by an additional one month each time, unless the closing of Denali’s initial business combination has occurred, without the need for any further